Bendamustine

CHEMBL487253 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

358.3 g/mol

LogP

2.9

Phase

4

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

분자량

358.3000 g/mol

LogP

2.90

TPSA

58.40 Å²

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

작용 기전

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21

InChI

InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)

Molecular Formula

C16H21Cl2N3O2

HBD / HBA

1 / 4

회전 가능 결합

9

무거운 원자

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Yes, Bendamustine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL487253. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 65628. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Bendamustine PillFYI에서

구조

핵심 데이터

분자식: C16H21Cl2N3O2
동의어: 4

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.